Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Primary:To evaluate the efficacy of satavaptan on top of conventional treatment in the
treatment of clinically evident ascites in participants with cirrhosis of the liver.
Secondary:To evaluate the tolerability and safety of satavaptan over a 52-week treatment
period in participants with cirrhosis of the liver and ascites.
The one-year double blind placebo controlled period is extended up to 2 years in a long term
safety study (PASCCAL-2).